Retinal Disorders

  • ID: 4421398
  • Report
  • 142 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

A range of disorders, some of which share similar underlying pathologies, can affect the retina and lead to progressively worsening vision and eventual blindness. The retina is the layer of light-sensitive tissue at the back of the eye that converts light into impulses to the brain via the optic nerve. A common feature of certain retinal disorders is abnormal growth of blood vessels in the macula, which can be effectively treated by drugs targeting vascular endothelial growth factor. These discrete indications are wet age-related macular degeneration, diabetic retinopathy with and without diabetic macular edema, and macular edema from retinal vein occlusion.
Note: Product cover images may vary from those shown
2 of 3
1 TREATMENT: RETINAL DISORDERS
  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Unmet Needs in Retinal Disorders
2 MARKETED DRUGS: RETINAL DISORDERS
  • Executive Summary
  • Product Overview
  • Product profile: Avastin
  • Product profile: Eylea
  • Product profile: Lucentis
  • Product profile: Ozurdex
3 PIPELINE: RETINAL DISORDERS
  • Executive Summary
  • Clinical Pipeline Overview
  • Product profile (late stage): Zuprata
  • Product profile (late stage): abicipar pegol
  • Product profile (late stage): brolucizumab
  • Product profile (late stage): squalamine
List of Figures
Figure 1: Structural diagram of the human eye
Figure 2: Surveyed respondents’ retinal disorder patient caseloads, by diagnosis
Figure 3: Retinal disorder pharmacological treatment rates, by indication and country
Figure 4: Leading therapies for retinal disorders across the US, Japan, and five major EU markets, by indication
Figure 5: Variation in anti-VEGF therapy uptake for retinal disorders across the US, Japan, and five major EU markets, by country
Figure 6: Patient share of retinal disorder drugs among first-line wet AMD patients, by country
Figure 7: Patient share of retinal disorder drugs among second-line and later wet AMD patients, by country
Figure 8: Patient share of retinal disorder drugs among DR with DME patients, by country
Figure 9: Patient share of retinal disorder drugs among DR without DME patients, by country
Figure 10: Patient share of retinal disorder drugs among ME from RVO patients, by country
Figure 11: Key unmet needs for retinal disorders
Figure 12: Avastin for retinal disorders - SWOT analysis
Figure 13: Drug assessment summary for Avastin in retinal disorders
Figure 14: Drug assessment summary for Avastin in retinal disorders
Figure 15: Eylea for retinal disorders - SWOT analysis
Figure 16: Drug assessment summary for Eylea in retinal disorders
Figure 17: Drug assessment summary for Eylea in retinal disorders
Figure 18: Lucentis for retinal disorders - SWOT analysis
Figure 19: Drug assessment summary for Lucentis in retinal disorders
Figure 20: Drug assessment summary for Lucentis in retinal disorders
Figure 21: Ozurdex for retinal disorders - SWOT analysis
Figure 22: Drug assessment summary for Ozurdex in retinal disorders
Figure 23: Drug assessment summary for Ozurdex in retinal disorders
Figure 24: Zuprata for retinal disorders - SWOT analysis
Figure 25: Drug assessment summary for Zuprata in retinal disorders
Figure 26: Drug assessment summary for Zuprata in retinal disorders
Figure 27: Abicipar pegol for retinal disorders - SWOT analysis
Figure 28: Drug assessment summary for abicipar pegol in retinal disorders
Figure 29: Drug assessment summary for abicipar pegol in retinal disorders
Figure 30: Brolucizumab for retinal disorders - SWOT analysis
Figure 31: Drug assessment summary for brolucizumab in retinal disorders
Figure 32: Drug assessment summary for brolucizumab in retinal disorders
Figure 33: Squalamine for retinal disorders - SWOT analysis
Figure 34: Drug assessment summary for squalamine in retinal disorders
Figure 35: Drug assessment summary for squalamine in retinal disorders

List of Tables
Table 1: Ophthalmologists surveyed for the retinal disorders primary research study, 2017
Table 2: Major retinal disorders involving ocular neovascularization
Table 3: Surveyed respondents’ retinal disorder patient caseloads, by diagnosis (%)
Table 4: Angiographic classification of neovascular lesions
Table 5: Segmentation of retinal vein occlusion patients according to central or branch involvement (%)
Table 6: Proportion of retinal disorder patients affected in both eyes (%)
Table 7: Major pharmacological treatments available for retinal disorders across the US, Japan, and five major EU markets
Table 8: Retinal disorder treatment strategies, by indication and country (%)
Table 9: Proportion of wet AMD patients at each line of therapy in the US, Japan, and five major EU markets, by country (%)
Table 10: Patient share of retinal disorder drugs among first-line wet AMD patients, by country (%)
Table 11: Patient share of retinal disorder drugs among second-line and later wet AMD patients, by country (%)
Table 12: Patient share of retinal disorder drugs among DR with DME patients, by country (%)
Table 13: Patient share of retinal disorder drugs among DR without DME patients, by country (%)
Table 14: Patient share of retinal disorder drugs among ME from RVO patients, by country (%)
Table 15: Key marketed drugs for retinal disorders
Table 16: Avastin drug profile
Table 17: Avastin late-phase trial data in retinal disorders
Table 18: Avastin ongoing late-phase clinical trial in retinal disorders
Table 19: Eylea drug profile
Table 20: Eylea pivotal trial data in retinal disorders
Table 21: Eylea ongoing late-phase clinical trial in retinal disorders
Table 22: Lucentis drug profile
Table 23: Lucentis pivotal trial data in retinal disorders
Table 24: Lucentis ongoing late-phase clinical trial in retinal disorders
Table 25: Ozurdex drug profile
Table 26: Ozurdex pivotal trial data in retinal disorders
Table 27: Ozurdex late-phase trial data in retinal disorders
Table 28: Phase III pipeline products in development for retinal disorders
Table 29: Zuprata drug profile
Table 30: Zuprata Phase II data in retinal disorders
Table 31: Zuprata Phase III trials in retinal disorders
Table 32: Abicipar pegol drug profile
Table 33: Abicipar pegol Phase II data in retinal disorders
Table 34: Abicipar pegol Phase III trials in retinal disorders
Table 35: Brolucizumab drug profile
Table 36: Brolucizumab Phase II data in retinal disorders
Table 37: Brolucizumab Phase III trials in retinal disorders
Table 38: Squalamine drug profile
Table 39: Squalamine Phase II data in retinal disorders
Table 40: Squalamine Phase III trials in retinal disorders
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll